Acadia Pharmaceuticals (ACAD) Cash from Investing Activities (2010 - 2026)

Acadia Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $66.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 153.43% year-over-year to $66.3 million; the TTM figure through Mar 2026 stood at -$112.2 million (up 20.15% YoY), while the FY2025 annual figure was -$302.6 million, down 890.78% from the prior year.
• Cash from Investing Activities was $66.3 million for Q1 2026 at Acadia Pharmaceuticals, up from -$55.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $192.5 million in Q1 2023 to a low of -$194.3 million in Q2 2023.
• Historically, Cash from Investing Activities has averaged -$9.5 million across 5 years, with a median of -$17.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 35301.73% in 2024, then tumbled 783.6% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$17.7 million in 2022, then jumped by 98.04% to -$347000.0 in 2023, then jumped by 35301.73% to $122.2 million in 2024, then slumped by 145.74% to -$55.9 million in 2025, then soared by 218.64% to $66.3 million in 2026.
• The last three Cash from Investing Activities figures came in at $66.3 million (Q1 2026), -$55.9 million (Q4 2025), and -$79.4 million (Q3 2025), per Business Quant data.